Retinal Disorder Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Type (Macular Degeneration, Diabetic Retinopathy, Others), By Dosage Form (Gels, Eye Solution, Capsules & Tablets, Eye Drops, Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By Region and Competition
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationRetinal Disorder Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Type (Macular Degeneration, Diabetic Retinopathy, Others), By Dosage Form (Gels, Eye Solution, Capsules & Tablets, Eye Drops, Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By Region and Competition
According to the National Eye Institute, the prevalence of AMD increases from 2% in people aged 50-59 years to 30% in people aged 75 years and older.
According to clinicaltrials.gov, as of March 2023, there are around 1,198 studies in different phases of development related to retinal disorders treatment across the globe.
Growing Prevalence of Retinal Disorders
According to the World Health Organization, an estimated 253 million people worldwide live with visual impairment, of whom 36 million are blind.
According to the American Academy of Ophthalmology, an estimated 11 million people in the United States have some form of AMD, with that number expected to increase as the population ages.
Advancements in Healthcare Technology
Advancements in healthcare technology are driving the global retinal disorder treatment market. New therapies and technologies are emerging that offer improved outcomes for patients with retinal disorders. For example, anti-vascular endothelial growth factor (anti-VEGF) therapy has revolutionized the treatment of AMD, helping to slow the progression of the disease and improve vision. Additionally, retinal implants and assistive devices are providing new options for patients with severe vision loss, in turn supporting the growth of global retinal disorder treatment market.
Additionally, assistive technologies such as virtual reality (VR) and augmented reality (AR) are being developed to help patients with retinal disorders. These technologies can simulate visual environments and provide feedback to help patients navigate their surroundings. For example, a VR headset can simulate a busy street, allowing patients to practice crossing the road safely. This in turn is expected to create lucrative opportunities for the growth of global retinal disorders treatment market in the next few years.
Supportive Government Initiatives
Retinal disorders are a major cause of visual impairment and blindness worldwide, affecting people of all ages and demographics. While there are several effective treatments found at for retinal disorders, access to these treatments varies widely across different countries and regions. In developed countries such as the United States, Canada, and much of Western Europe, retinal disorder treatment is generally well-established and widely found at. In developing countries, however, access to retinal disorder treatment is often limited by a lack of resources, infrastructure, and trained healthcare professionals. Many people with retinal disorders in these countries are unable to receive the care they need, leading to a higher incidence of vision loss and blindness.
One such initiative was the World Health Organization's Vision 2020 program, which aimed to eliminate avoidable blindness by the year 2020.
Market Segmentation
Global Retinal Disorder Treatment Market can be segmented by type, by dosage form, by distribution channel, and by region. Based on type, Global Retinal Disorder Treatment market can be categorized into macular degeneration, diabetic retinopathy, and others. By dosage form, the Global Retinal Disorder Treatment market can be segmented into gels, eye solution, capsules & tablets, eye drops, and others. By distribution channel, the Global Retinal Disorder Treatment market can be fragmented into hospital pharmacy, online pharmacy, and retail pharmacy. Regionally, the global Retinal Disorder Treatment market can be segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.
Market Players
Santen Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Graybug Vision, Inc., Shire (Takeda Pharmaceutical Company Limited), Bayer AG, Genentech, Inc., Acucela Inc., Pfizer, Inc., Kubota Pharmaceutical Holdings Co., Ltd., Allergan plc. (AbbVie Inc.), among others are some of the leading players operating in the global Retinal Disorder Treatment market.
Recent Developments
- In 2017, the U.S. Foodand Drug Administration approved the first gene therapy for an inheritedretinal disorder called Leber congenital amaurosis. This therapy, calledLuxturna, uses a virus to deliver a healthy copy of a defective gene to theretina, which can improve vision in people with the disorder. Since then,several other gene therapies for retinal disorders have been tested in clinicaltrials, with promising results.
- In 2019, a team ofresearchers at the University of California, Los Angeles, announced that theyhad successfully used stem cells to restore vision in mice with retinaldegeneration. The researchers hope to begin human clinical trials in the nearfuture.
- In 2019, the U.S. Foodand Drug Administration approved a new drug called Beovu for the treatment ofwet age-related macular degeneration, a common retinal disorder that can leadto vision loss. Beovu works by targeting a protein called VEGF, which can causeabnormal blood vessel growth in the retina. The drug has been shown to be effectiveat reducing the progression of the disease and improving vision in people withwet age-related macular degeneration.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | By Type By Dosage Form By Distribution Channel By Region |
| Regional scope | North America, Europe, Asia Pacific, South America, Middle East & Africa |
| Key companies profiled | Santen Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Graybug Vision, Inc., Shire (Takeda Pharmaceutical Company Limited), Bayer AG, Genentech, Inc., Acucela Inc., Pfizer, Inc., Kubota Pharmaceutical Holdings Co., Ltd., Allergan plc. (AbbVie Inc.) |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy